華森製藥(002907.SZ):變更藥品生產許可證
格隆匯3月22日丨華森製藥(002907.SZ)公佈,公司於近日收到重慶市藥品監督管理局頒發的《藥品生產許可證》,本次主要涉及生產場地變更、增加生產範圍、新增委託生產用於MAH轉讓。變更內容為:
(一)品種變更生產場地:茶愈膠囊(國藥準字:H10930159)生產場地變更為重慶市榮昌區昌州街道板橋路143號503車間硬膠囊劑生產線;
(二)西洛他唑片(國藥準字H20046390)生產場地變更為:重慶市榮昌區工業園區一車間片劑生產線;重慶市榮昌區昌州街道板橋路143號503車間片劑生產線;
(三)注射用奧美拉唑鈉(國藥準字H20163061)生產場地變更為:重慶市榮昌區昌州街道板橋路143號502車間凍乾粉針劑生產線。
(四)新增生產範圍:重慶市榮昌區工業園區增加生產範圍“滴劑”(膠囊型)。
(五)新增委託生產用於MAH轉讓:受託方是海南益爾藥業有限公司,生產場地是海口市美蘭區靈山鎮順路達4號中藥提取車間、口服固體制劑車間硬膠囊劑生產線,委託品種是蒼耳子鼻炎膠囊,委託有效期至2025年2月6日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.